iScience (Nov 2024)

MOTS-c modulates skeletal muscle function by directly binding and activating CK2

  • Hiroshi Kumagai,
  • Su-Jeong Kim,
  • Brendan Miller,
  • Hirofumi Zempo,
  • Kumpei Tanisawa,
  • Toshiharu Natsume,
  • Shin Hyung Lee,
  • Junxiang Wan,
  • Naphada Leelaprachakul,
  • Michi Emma Kumagai,
  • Ricardo Ramirez, II,
  • Hemal H. Mehta,
  • Kevin Cao,
  • Tae Jung Oh,
  • James A. Wohlschlegel,
  • Jihui Sha,
  • Yuichiro Nishida,
  • Noriyuki Fuku,
  • Shohei Dobashi,
  • Eri Miyamoto-Mikami,
  • Mizuki Takaragawa,
  • Mizuho Fuku,
  • Toshinori Yoshihara,
  • Hisashi Naito,
  • Ryoko Kawakami,
  • Suguru Torii,
  • Taishi Midorikawa,
  • Koichiro Oka,
  • Megumi Hara,
  • Chiharu Iwasaka,
  • Yosuke Yamada,
  • Yasuki Higaki,
  • Keitaro Tanaka,
  • Kelvin Yen,
  • Pinchas Cohen

Journal volume & issue
Vol. 27, no. 11
p. 111212

Abstract

Read online

Summary: MOTS-c is a mitochondrial microprotein that improves metabolism. Here, we demonstrate CK2 is a direct and functional target of MOTS-c. MOTS-c directly binds to CK2 and activates it in cell-free systems. MOTS-c administration to mice prevented skeletal muscle atrophy and enhanced muscle glucose uptake, which were blunted by suppressing CK2 activity. Interestingly, the effects of MOTS-c are tissue-specific. Systemically administered MOTS-c binds to CK2 in fat and muscle, yet stimulates CK2 activity in muscle while suppressing it in fat by differentially modifying CK2-interacting proteins. Notably, a naturally occurring MOTS-c variant, K14Q MOTS-c, has reduced binding to CK2 and does not activate it or elicit its effects. Male K14Q MOTS-c carriers exhibited a higher risk of sarcopenia and type 2 diabetes (T2D) in an age- and physical-activity-dependent manner, whereas females had an age-specific reduced risk of T2D. Altogether, these findings provide evidence that CK2 is required for MOTS-c effects.

Keywords